HM
BIOSU

Howard Marks’s BioPlus Acquisition Corp. Unit BIOSU Stock Holding History

Howard Marks’s Portfolio BIOSU Stock Details BIOSU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100,000
Closed -$1M – 416
2021
Q4 		$1M Buy
+100,000
New +$1M 0.01% 298

Other funds holding BIOSU

Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
ACM
Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Howard Marks's BIOSU Position: Q1 2022 in Review

Howard Marks sold out of BioPlus Acquisition Corp. Unit (BIOSU) in Q1 2022, closing a stake of 100,000 shares — an estimated $1M sold.

Howard Marks first reported a position in BIOSU in Q4 2021 and held it in 1 quarter. The position peaked at $1M in Q4 2021. 30 funds tracked by Wall St. Rank hold BIOSU as of Q1 2022.

  • Howard Marks reported no remaining BioPlus Acquisition Corp. Unit position as of Q1 2022 after selling out during the quarter.
  • Howard Marks sold 100,000 BioPlus Acquisition Corp. Unit shares in Q1 2022, an estimated $1M.
  • Howard Marks first reported a position in BioPlus Acquisition Corp. Unit in Q4 2021 and held it in 1 quarter.
  • Howard Marks's BioPlus Acquisition Corp. Unit position peaked at $1M in Q4 2021.
  • 30 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Unit as of Q1 2022.

Based on Oaktree Capital Management's 13F filing for Q1 2022, filed 16 May 2022.